Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLARIS: pembrolizumab + lenvatinib in advanced hepatocellular carcinoma after failure of atezolizumab/bevacizumab or other IO-based therapy
2021-000355-40Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Jun 2021; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2021-000355-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000355-40.